JP2016503293A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503293A5
JP2016503293A5 JP2015540154A JP2015540154A JP2016503293A5 JP 2016503293 A5 JP2016503293 A5 JP 2016503293A5 JP 2015540154 A JP2015540154 A JP 2015540154A JP 2015540154 A JP2015540154 A JP 2015540154A JP 2016503293 A5 JP2016503293 A5 JP 2016503293A5
Authority
JP
Japan
Prior art keywords
seq
antibody
composition
cdr
binding member
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015540154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503293A (ja
JP6333271B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/073009 external-priority patent/WO2014068132A1/en
Publication of JP2016503293A publication Critical patent/JP2016503293A/ja
Publication of JP2016503293A5 publication Critical patent/JP2016503293A5/ja
Application granted granted Critical
Publication of JP6333271B2 publication Critical patent/JP6333271B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015540154A 2012-11-05 2013-11-05 IL−1βへの結合メンバー Expired - Fee Related JP6333271B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261722532P 2012-11-05 2012-11-05
US61/722,532 2012-11-05
EP12007503 2012-11-05
EP12007503.1 2012-11-05
PCT/EP2013/073009 WO2014068132A1 (en) 2012-11-05 2013-11-05 Binding members to il-1 beta

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018083160A Division JP6779252B2 (ja) 2012-11-05 2018-04-24 IL−1βへの結合メンバー

Publications (3)

Publication Number Publication Date
JP2016503293A JP2016503293A (ja) 2016-02-04
JP2016503293A5 true JP2016503293A5 (enExample) 2016-12-08
JP6333271B2 JP6333271B2 (ja) 2018-06-06

Family

ID=47146146

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015540154A Expired - Fee Related JP6333271B2 (ja) 2012-11-05 2013-11-05 IL−1βへの結合メンバー
JP2018083160A Expired - Fee Related JP6779252B2 (ja) 2012-11-05 2018-04-24 IL−1βへの結合メンバー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018083160A Expired - Fee Related JP6779252B2 (ja) 2012-11-05 2018-04-24 IL−1βへの結合メンバー

Country Status (11)

Country Link
US (5) US9404930B2 (enExample)
EP (2) EP3750917A1 (enExample)
JP (2) JP6333271B2 (enExample)
KR (1) KR102345999B1 (enExample)
CN (1) CN104870015B (enExample)
BR (1) BR112015009892B1 (enExample)
CA (1) CA2888583C (enExample)
MX (1) MX374817B (enExample)
PL (1) PL2914287T3 (enExample)
RU (1) RU2711118C2 (enExample)
WO (2) WO2014068132A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374817B (es) * 2012-11-05 2025-03-06 Delenex Therapeutics Ag Miembros de union para il-1 beta.
CN106661574B (zh) 2014-08-29 2019-12-06 先锋国际良种公司 涉及油基质的方法和装置
US9078427B1 (en) 2014-08-29 2015-07-14 Pioneer Hi Bred International Inc Method of storing plant embryos
JP6202652B1 (ja) * 2016-12-19 2017-09-27 株式会社ヘルスケアシステムズ 抗エクオール抗体組成物及びその利用
CN107362351B (zh) * 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2020176210A1 (en) 2019-02-28 2020-09-03 Exxonmobil Chemical Patents Inc. Catalyst compositions and precursors, processes for making the same and syngas conversion processes
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
CA3201637A1 (en) 2020-11-18 2022-05-27 Novartis Ag Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
AU2021405066A1 (en) * 2020-12-23 2023-06-22 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2022136693A1 (en) * 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
CN116783218A (zh) * 2020-12-23 2023-09-19 努玛治疗有限公司 具有降低的免疫原性的抗体可变结构域和抗体
CN113908589B (zh) * 2021-10-08 2022-09-27 天津工业大学 一种表面印迹抗体的疏水电荷诱导模式膜层析介质及其制备方法
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
CN116068192A (zh) * 2022-01-24 2023-05-05 中国农业大学 一种检测非洲猪瘟病毒抗体的ELISA检测试剂盒以及protein L的应用
JP2026520185A (ja) * 2023-06-13 2026-06-22 メルク・シャープ・アンド・ドーム・エルエルシー インターロイキン-1ベータを捕捉するための環状ペプチドの使用方法
CN119735676B (zh) * 2023-12-26 2025-12-16 华润生物医药有限公司 抗tslp抗体及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
CN102093477B (zh) 2002-05-22 2014-02-26 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
JP4538461B2 (ja) * 2003-01-24 2010-09-08 アプライド モレキュラー エボリューション,インコーポレイテッド ヒトIL−1βアンタゴニスト
EP2361933A3 (en) * 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
EP1891110A2 (en) 2005-06-07 2008-02-27 Esbatech AG STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
HRP20130042T1 (hr) * 2008-06-06 2013-03-31 Xoma Technology Ltd. Postupci lijeäśenja reumatoidnog artritisa
GB2461273A (en) 2008-06-24 2009-12-30 Seppo Haekkinen Load monitoring system
GB0811574D0 (en) 2008-06-24 2008-07-30 Trillion Genomics Ltd Characterising planar samples by mass spectrometry
PL2307455T3 (pl) 2008-06-25 2017-09-29 Esbatech, An Alcon Biomedical Research Unit Llc Optymalizacja rozpuszczalności cząsteczek immunowiążących
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
AU2009289547A1 (en) 2008-09-05 2010-03-11 Xoma (Us) Llc Methods for treating or preventing IL-1beta related diseases
WO2012034039A2 (en) 2010-09-10 2012-03-15 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
MX374817B (es) * 2012-11-05 2025-03-06 Delenex Therapeutics Ag Miembros de union para il-1 beta.

Similar Documents

Publication Publication Date Title
AU2025283534A1 (en) TREM2 antigen binding proteins and uses thereof
CN105849124B (zh) 双重特异性抗体
TWI769537B (zh) 標靶bcma的抗體、雙專一性抗體及其用途
JP2026077815A (ja) ヒトil-4受容体に対する高親和性ヒト抗体
JP6779252B2 (ja) IL−1βへの結合メンバー
AU2012315474B2 (en) Antibodies against TL1a and uses thereof
RU2016141561A (ru) Связывающие элементы к фно-альфа
CN115397852B (zh) 工程化抗il-2抗体
US12325739B2 (en) Bispecific SARS-CoV-2 antibodies and methods of use
JP2012518425A5 (enExample)
RU2012130840A (ru) Соединения
JP2016503412A5 (ja) Il−6アンタゴニストおよびその使用
WO2014095808A1 (en) Antibodies against il-1 beta
CN104903352A (zh) 多价结合蛋白组合物
CN109069606B (zh) 干扰素β抗体及其用途
CN106565840B (zh) 抗乙肝表面抗原的抗体及其用途
TWI801425B (zh) Il-5 抗體、其抗原結合片段及醫藥用途
WO2026012501A1 (zh) 一种抗ngf单克隆抗体及其应用
WO2022100664A1 (zh) 一种tslp抗原结合蛋白及其应用
CN114846026A (zh) 对人il-13和il-17具有结合特异性的多特异性抗体
JP2021533806A5 (enExample)
TW202413405A (zh) 抗體、其抗原結合片段及其藥物用途
WO2025153079A1 (en) Method of treatment
TW202604946A (zh) 結合ige之抗體及抗體片段
RU2852376C2 (ru) Антитела с двойной специфичностью